Exploring the Role of Paraoxonases in the Pathogenesis of Coronary Artery Disease: A Systematic Review

David Abelló 1,†, Elena Sancho 1,‡, Jordi Camps 1,2,* and Jorge Joven 1,2,*

1 Department of Medicine and Surgery, Faculty of Medicine and Health Sciences, Rovira i Virgili University, C. Sant Llorenç, s/n, Reus, Catalonia 43201, Spain; E-Mails: davidabellouaudi@gmail.com (D.A.); sancho.08@hotmail.com (E.S.)
2 Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, C. Sant Joan, s/n, Reus, Catalonia 43201, Spain

† These authors contributed equally to this work.

* Authors to whom correspondence should be addressed;
E-Mails: jorge.joven@urv.cat (J.J.); jcamps@grupsagessa.com (J.C.);
Tel.: +34-977-310-300 (ext. 55330) (J.J.); +34-977-310-300 (ext. 55409) (J.C.).

External Editor: Francis J. Miller Jr.

Received: 23 October 2014 / Accepted: 10 November 2014 / Published: 14 November 2014

Abstract: Paraoxonases (PON) are three enzymes (PON1, PON2 and PON3) that play a role in the organism’s antioxidant system; alterations in which are associated with diseases involving oxidative stress. In this review, we summarize the evidence of PON related to the pathogenesis of coronary artery disease (CAD) and atherosclerosis. We searched three electronic databases (PubMed, Scopus and Cochrane Database) with no date limit. All of the articles selected investigated PON enzymatic activity and/or PON gene polymorphisms. The selection focused on PON in relation to atherosclerosis, CAD and myocardial infarction. The exclusion criteria were a sample size <100 patients, non-human studies, editorials and systematic reviews without restrictions on the country of origin. With these criteria, we identified thirty-five prospective studies published between 1986 and 2014 with a total of 28,164 participants. The relationship between PON gene polymorphisms and CAD was not conclusive, but most studies support the concept that alterations in PON1 enzymatic activity levels do influence atheroma formation. Conversely, relationships between PON2 and PON3 vs. CAD have not been extensively investigated. Our review of the current data concludes that the bases of paraoxonases
involvement in atherosclerosis are poorly understood and that this issue requires future comprehensive, multi-centered studies.

**Keywords:** atherosclerosis; coronary artery disease; myocardial infarction; oxidative stress; paraoxonase; systematic review

1. Introduction

The paraoxonases (PON) are enzymes involved in oxidative stress, in the atherosclerosis process and, consequently, in vascular disease. However, their specific role in these clinical derangements is still under debate, and we sought definitive conclusions by evaluating published studies.

The PON family contains three enzymes: PON1, PON2 and PON3. Their genes are located adjacent to each other on chromosome 7q21-22 [1,2]. Several polymorphisms have been reported for the PON genes in the coding, as well as the promoter regions; alterations that influence the activities and/or concentrations of these enzymes to a greater or lesser extent [2–5]. PON1 and PON3 are found in many tissues, as well as in circulation, associated with high-density lipoproteins (HDL), while PON2 is exclusively intracellular [6–9].

PON1 was initially described as an organophosphate hydrolase, and its role in insecticide poisoning has been extensively reported [10]. Subsequent studies demonstrated that PON1 also had a lactonase activity and is able to hydrolyze lipophilic lactones and degrade oxidized lipids in lipoproteins and in cells [11,12]. This property enabled investigators to propose that PON1 plays a key role in the protection against atherosclerosis and its related systemic diseases [1].

PON2 and PON3 are also able to hydrolyze lactones similar to PON1, and they have also been implicated in the atherosclerosis process. Nevertheless, their modes of action have been shown not to be exactly equivalent to that of PON1, and further investigations are needed to fully clarify their roles. The antiatherogenic effect of PON2 could be attributed to the protection of mitochondria against oxidative stress, while PON3 has been shown to be a protective factor against obesity. As such, new and interesting lines of research are opened up. To summarize, the three members of the PON family are related genetically, possess lactonase activity and are involved in the atherosclerosis process [6].

The aim of this systematic review is to update and clarify the scientific evidence available on PON enzymes and their roles in cardiovascular disease. We provide, here, a novel approach integrating PON gene polymorphisms, their enzymatic activities and their correlation with atherosclerosis.

2. Methodology and Search Strategy

2.1. Search Strategy

The search was performed in three electronic databases: PubMed, Scopus and Cochrane. Article selection was performed in July 2014, and no date limit was applied to articles selected. Studies included were restricted to those on humans and to English-language journals. Search terms were combined using Boolean operations. The search terms included: (“Paraoxonases” OR “PON”) AND (“myocardial infarction” OR “CHD” OR “vascular disease” OR “atherosclerosis”). Initially,
the referenced articles were manually screened independently by two investigators of the team. The first screening selection was based on the article’s title and a second screening on the abstract. All duplicate publications were omitted.

2.2. Selection Criteria

All of the articles involved in PON enzymatic activity and/or PON gene polymorphisms were selected. The selection focused on the PON relationship with atherosclerosis, coronary artery disease (CAD) and myocardial infarction (MI). Other diseases and comorbidities were excluded.

The exclusion criteria were a sample size of <100 patients, non-human studies, editorials and systematic reviews. No country distinctions were applied.

2.3. Data Extraction

Data were extracted and pooled and included: year of publication, sample size, type of study, disease observed and the polymorphisms studied. Because serum PON1 possesses a wide catalytic versatility and is able to hydrolyze a variety of substrates [6], the measurement methods of the publications were also considered. Main conclusions were summarized, and missing data were obtained directly from the respective corresponding authors. In some cases, these data were not forthcoming, and the studies were deleted from our analysis.

3. Results

3.1. Identification of Studies

The initial electronic search of the above-mentioned databases identified 502 articles (Figure 1). After exclusion of duplicates (n = 215) and with 201 contributions considered irrelevant based on the titles and 37 on the abstract, the selection was reduced to 49 full-text articles. Subsequently, studies (n = 14) with missing data or without compliance with inclusion or exclusion criteria were discarded. Finally, 35 manuscripts were included in this systematic review [13–47]. The process of selection is depicted in Figure 1.

3.2. Study Characteristics

The overall study characteristics are displayed in Table 1. All of the articles were prospective studies focusing on the influence of PON enzymes in CAD, MI and atherosclerosis. Most of them were case-control studies. They were published between 1986 and 2014 and included a total of 28,164 participants. Eighteen manuscripts investigated the relationship of the gene polymorphisms with disease, while eight investigated the enzymatic activity in relation to disease; only nine analyzed both variables. The main substrates used to measure PON1 enzyme activity were paraoxon (paraoxonase activity) and phenylacetate (arylesterase activity) in 12 and eight studies, respectively. Some studies employed homocysteine thiolactones as substrates (hcy-thiolactonase activity).
Figure 1. Flow chart of study selection and review.

- **Identification**:
  - Number of results from PubMed: $n = 202$
  - Number of results from Scopus: $n = 291$
  - Number of results from Cochrane: $n = 9$
  - **Pooled articles**: $n = 502$
    - 215 duplicates removed
  - **Unique articles**: $n = 287$
    - 201 excluded as irrelevant from title
  - **Potential articles**: $n = 86$
    - 37 excluded as irrelevant from abstract
  - **Full text review**: $n = 49$
    - 14 excluded as missing data or non-conforming inclusion criteria
  - **Included articles**: $n = 35$
Table 1. Characteristics of the included studies. ATH, atherosclerosis; C, cohort; CAD, coronary artery disease; CC, case-control; CS, cross-sectional; EA, enzyme activity; GP, genetic polymorphism; MI, myocardial infarction.

| First author         | Year | Location of the studied population | Type of study | Patients (n) | Disease | Object of study | Enzyme activity | Reference number |
|----------------------|------|------------------------------------|---------------|-------------|---------|----------------|-----------------|-----------------|
| Liu, T.              | 2014 | China                              | CC            | 2456        | CAD     | √              | Paraoxonase-arylesterase | 13              |
| Shekhanawar, M.      | 2013 | India                              | CS            | 110         | CAD     | -              | Arylesterase     | 14              |
| Cozzi, L.            | 2013 | Italy                              | CC            | 105         | MI      | √              | -               | 15              |
| Tang, W.H.W.         | 2012 | USA                                | C             | 3668        | CAD MI  | √              | Paraoxonase-arylesterase | 16              |
| Bayrak, A.           | 2012 | Turkey                             | CC            | 270         | CAD     | √              | Thiolactonase-panaoxonase | 17              |
| Saxena, T.           | 2011 | India                              | CC            | 150         | MI      | -              | Paraoxonase      | 18              |
| Gluba, A.            | 2010 | Poland                             | CC            | 407         | MI      | √              | -               | 19              |
| Lakshmy, R.          | 2010 | India                              | CC            | 345         | MI      | √              | Paraoxonase      | 20              |
| Regieli, J.J.        | 2009 | Netherlands                        | C             | 793         | CAD     | √              | -               | 21              |
| Jayakumari, N.       | 2009 | India                              | CC            | 574         | CAD     | -              | Arylesterase     | 22              |
| Yildiz, A.           | 2008 | Turkey                             | CC            | 134         | CAD     | -              | Paraoxonase      | 23              |
| Saeed, M.            | 2007 | Pakistan                           | CC            | 581         | MI      | √              | -               | 24              |
| Jarvik, G.P.         | 2003 | USA                                | CC            | 437         | CAD     | √              | Arylesterase     | 25              |
| Domagala, T.B.       | 2006 | U.K.                               | CC            | 475         | CAD     | √              | Thiolactonase-panaoxonase | 26              |
| Su, S.               | 2005 | China                              | CC            | 423         | CAD     | √              | Arylesterase     | 27              |
| Rodríguez-Esparraóñ, F. | 2005 | Spain                              | CC            | 619         | CAD     | √              | -               | 28              |
| Kabarolu, C.         | 2004 | Turkey                             | CC            | 103         | CAD MI  | -              | Paraoxonase      | 29              |
| Srinivasan, S.R.     | 2004 | USA                                | C             | 1786        | ATH     | √              | -               | 30              |
| Göçmen, A.Y.         | 2004 | Turkey                             | CC            | 172         | CAD     | -              | Paraoxonase      | 31              |
| Oliveira, S.A.       | 2004 | Brazil                             | CC            | 732         | CAD     | √              | -               | 32              |
| Robertson, K.S.      | 2003 | U.K.                               | C             | 3052        | CAD     | √              | -               | 33              |
| Wang, X.             | 2003 | China                              | CC            | 949         | CAD     | √              | Arylesterase     | 34              |
| Fortunato, G.        | 2003 | Italy                              | C             | 310         | ATH     | √              | -               | 35              |
| Rahmani, M.          | 2002 | Iran                               | CC            | 251         | CAD     | -              | Paraoxonase-arylesterase | 36              |
| Ferré, N.            | 2002 | Spain                              | CC            | 215         | MI      | √              | Paraoxonase      | 37              |
| Hong, S.H.           | 2001 | Korea                              | CC            | 304         | CAD     | -              | -               | 38              |
| Malin, R.            | 2001 | Finland                            | CS            | 123         | ATH     | √              | -               | 39              |
| Gardemann, A.        | 2000 | Germany                            | C             | 2784        | CAD MI  | √              | -               | 40              |
| Cascorbi, I.         | 1999 | Germany                            | CC            | 2000        | CAD     | √              | -               | 41              |
| Sanghera, D.K.       | 1998 | USA                                | CC            | 318         | CAD MI  | √              | -               | 42              |
| Ombres, D.           | 1998 | Italy                              | CC            | 472         | CAD     | √              | -               | 43              |
| Sanghera, D.K.       | 1997 | India-China                        | CC            | 1034        | CAD     | √              | -               | 44              |
| Suehiro, T.          | 1996 | Japan                              | CC            | 386         | CAD MI  | √              | -               | 45              |
| Herrmann, S.M.       | 1996 | France                             | CC            | 1343        | MI      | √              | -               | 46              |
| McElveen, J.         | 1986 | U.K.                               | CC            | 283         | MI      | -              | Paraoxonase      | 47              |
3.3. PON Genetic Polymorphisms and CAD

We found that the influence of the several PON genetic polymorphisms on CAD was not generally substantiated. Several studies [13,15,19–21,24,32–34,42,44] found associations between one or more polymorphisms of the PON genes vs. the disease. The strongest association was found with PON1 Q192R polymorphism, specifically reporting a protective role of the 192Q allele and a deleterious effect of the 192R allele [13,19,20,24,42,44]. However, conflicting results were reported in some manuscripts [21,34] in which the 192Q allele was more frequent in CAD patients, in contradiction to the other studies. Other PON1 and PON2 polymorphisms (M55L, C-108T, R-160G, G-162A from PON1 and S311C and A148G from PON2) have been associated with cardiovascular disease [24,32–34]. One article [32] suggested that the 55M allele of PON1 has a protective effect against CAD, while other studies [21,33] stated the opposite. Some articles [15,33,34,42] found a higher frequency of 311S and 311C alleles in CAD patients. Adding more confusion to the debate, several studies failed to find any kind of relationship between PON polymorphisms and CAD [16,17,25,26,28,35,37–41,43,45,46].

The hypothesis that variations in the PON genes were predictive factors for CAD or MI has also been investigated, and again, the results have been conflicting; some articles [25,32,40,41,43,45] negate this hypothesis, while others [39,40] note a relationship between the 55L and 192R alleles as positively associated with the severity of CAD.

The possibility remains that these contradictory outcomes result from ethnic differences, as illustrated by comparisons of African Americans vs. white Americans [30] or Indian vs. Chinese populations [44]. However, these findings appear to be anecdotal, and we could not find any association between ethnicity or country of origin and the influence of PON gene polymorphisms on CAD. Additionally, where countries provide more than one study, the conclusions are contradictory in terms of association vs. no association or positive association vs. negative association (Figure 2).

Figure 2. Country of origin and outcomes of studies investigating the possible association between PON gene polymorphisms and CAD.
3.4. PON1 Genetic Polymorphisms and Enzymatic Activity in CAD

There were seven articles evaluating the influence of Q192R and M55L PON1 polymorphisms on the paraoxonase, arylesterase or hcy-thiolactonase PON1 activity in patients with CAD. There is a complete agreement that the 192R allele increases and the 192Q allele decreases paraoxonase activity in CAD patients, as well as in the healthy population [13,16,17,20]. Similar results have been found for hcy-thiolactonase activity [5,18]. With respect to the M55L polymorphism, the 55L allele has been associated with increased paraoxonase and hcy-thiolactonase activities, while the 55M allele is associated with reduced enzyme activities [16,20,26]. Few data refer to arylesterase activity and its relationship between PON1 polymorphisms in patients with CAD. Jarvik et al. [25] reported that the PON1-162/-108/55/192 haplotype did not predict arylesterase activity. However, Liu et al. [13] noted that the 192R allele decreases this activity, albeit to a lesser extent to that of paraoxonase activity.

3.5. PON1 Enzymatic Activity, Atherosclerosis and CAD

The PON family appears to play an important role in the process of the atheroma plaque formation, but mechanisms are difficult to establish. Several articles support the hypothesis that lower serum PON1 activity is related to an increase in plaque formation and, consequently, to a higher risk of cardiovascular disease. Bayrak et al. [17] measured the paraoxonase and hcy-thiolactonase activities of PON1 and the Q192R polymorphism in patients with angiography-detected CAD and in control subjects. Their results showed significantly lower paraoxonase and hcy-thiolactonase activities in the CAD group, together with a non-significant trend towards decreased HDL concentrations. However, Domagala et al. [26] observed higher hcy-thiolactonase activities in CAD patients compared to controls; albeit the serum PON1 protein concentration was lower in the CAD group. None of these articles had the measured results adjusted for known risk factors for atherosclerosis (including smoking habit, BMI, serum cholesterol, triglycerides). Conversely, Ferré et al. [37] performed a multivariate analysis where the patients were matched for genotype, BMI and age. They found significant differences in paraoxonase and arylesterase activities between patients and controls, but these differences ceased when the genotypes were included in the statistical analysis.

Kabarolgu et al. [29] showed that having a low serum PON1 activity was associated with a higher degree of atherosclerosis in patients with confirmed MI or unstable angina pectoris. In addition, several articles [14,22,31] support the hypothesis that lower PON1 activity is correlated with an increase in oxidative stress, leading to the development of atherosclerosis. All of these studies showed significant associations between lower PON1 activity, oxidative stress and CAD. There is no agreement as to whether serum cholesterol and triglyceride concentrations are associated with serum PON1 activity since, despite there being one report [31] of a positive correlation; other reports [14,22] observed a negative correlation. In contrast to these data, investigations conducted in Iran [36] showed no differences in PON1 paraoxonase and arylesterase activities between CAD patients and healthy individuals. Several articles reported lower serum paraoxonase activity in patients with MI in comparison to the control group [18,37,47]. However, it is not known whether this low paraoxonase activity plays a causative role in the pathogenesis of MI or is a consequence of this derangement.
In terms of prevention and prediction of CAD and mortality, a significant correlation was found [16] between lower paraoxonase and arylesterase and an increased risk of major adverse cardiac events (death, myocardial infarction and stroke). Further, these changes in PON activity were related to a greater risk for subclinical myocardial necrosis. Furthermore, lower PON activity was observed in men than in women.

We found one study investigating serum PON1 activity in relation to alterations in coronary blood flow [23]. The results showed that reduced serum PON1 activity might be a biochemical marker of slow coronary flow in patients with angiography-confirmed non-stenosis coronary arteries

In summary, most articles we had identified agreed that serum PON1 paraoxonase activity is decreased in patients with CAD or MI, relative to healthy individuals. Only two articles [20,36] did not find any differences between such groups. Arylesterase activity was reported to be decreased in CAD patients in four articles [13,16,22,27] and unchanged in two [34,36]. More conflict exists regarding hcy-thiolactonase activity. Only two articles studied this parameter, one of which [17] concluded that hcy-thiolactonase activity is decreased in CAD patients, while the other [26] stated that this activity is increased.

4. Discussion

Studies of PON enzymes require complex methodology, and small methodological differences can yield contradictory results. For example, with respect to PON1 activity (the most extensively investigated enzyme from the PON family), the current use of synthetic substrates limits the interpretation of the data, since it is not clear whether these measured activities reflect the real endogenous physiological activity of the enzyme. Experimental evidence suggests that, essentially, the lactonase assay measures PON1 that is tightly bound to HDL particles, while the esterase assay measures the tightly-, as well as the loosely-, bound enzyme [48]. The differences between methods, therefore, can be related to differences in the structure and composition of the HDL particles caused by the disease process. There is the possibility that these changes affect PON1 activity, and this is further influenced by the type of substrate used to measure PON1 [49]. Indeed, there is evidence that various elements within PON1’s milieu that regulate its different activities may interact with components of the human carotid atherosclerotic lesions, which are in constant contact with circulating HDL-associated PON1 [50].

Further confusions arise from serum PON1 activity being strongly determined by the enzyme genotype [51,52]. Hence, in case-control studies evaluating enzyme activity, it is imperative that cases and controls are matched for genotype. If not, it would not be possible to ascertain whether the observed changes are due to the disease per se or to coincidental differences in allelic frequencies between cases and controls. This is especially true when the reported sample sizes are small, i.e., gene-association studies should be performed with a large sample size involving at least several hundred participants. The extent of the genetic contribution to complex diseases is difficult to ascertain, and the individual contribution of each gene is likely to be modest. Thus, taking into account that the analysis of allele frequencies uses a simple $\chi^2$ test, the observed associations between a given polymorphism and a particular disease may be merely coincidental. Since a $p$-value of 0.05 is accepted as confirmation of statistical significance, by definition, there is a 5% possibility that a positive result is obtained by chance alone. Increasing the sample size minimizes this risk [53].
Of note is that we found a higher rate of association between PON1 gene polymorphisms and CAD in the articles from 2004 onward, compared to the earlier studies. Of the articles published in the last 10 years, 64% showed an association between PON1 gene polymorphisms and CAD, in contrast to 42% of the articles published before 2004. This observation may be related, perhaps, to changes in the methodology and/or design, and changes in these results may be expected in future investigations.

There is a lack of consensus on the definitions of the outcomes studied, including oxidative stress, arteriosclerosis, artery wall thickness and CAD. Some articles used, as inclusion criteria, the risk factors for arteriosclerosis and previous atherothrombotic events [15], while other studies measured specifically the extent of arteriosclerosis and of CAD diagnosed either with angiography [16], or with electrocardiogram and clinical symptomatology [14], or by measuring coronary blood flow [23]. It is of note that all articles that had studied patients with MI merely considered the surviving subjects in the analyses. This constitutes an important selection bias. Further, comparisons of groups that had included smokers, high-alcohol consumption, hypertension and diabetes mellitus [13,15,18–24,27–29,32,34,39] may need to be re-assessed.

We could find no conclusive relationship between PON1 polymorphisms and CAD or MI. However, there is a consensus on polymorphisms influencing PON1 enzymatic activity, both in the healthy population and in CAD patients. Further, most studies support the concept that alterations in PON1 enzymatic activity levels are associated with oxidative stress, a higher degree of atheromatous plaque formation and poorer clinical outcomes. Nevertheless, there appears to be a step missing that precludes us relating the PON1 genetic polymorphisms with outcomes (CAD or MI). Indeed, variable expressions of PON1, PON2 and PON3 have been detected in macrophages and smooth muscle cells of human atheroma plaques [54,55]. However, the relationships between alterations in the peripheral blood and the expression of the three PON enzymes in human atheroma tissue have not been extensively investigated and are poorly understood [56]. Another aspect of note is the paucity of information on the relationships between PON2 and PON3 gene polymorphisms and enzymatic activities vs. cardiovascular disease. This is relevant, since experimental studies in animals and in cultured cells suggest that these two enzymes play an important role in the protection against oxidative stress [5,57–60]. However, there has been a dearth of physiological evidence in clinical studies relating these enzymes with disease, i.e., their contributions to atherosclerosis and CAD need elucidation. Further, PON1, PON2 and PON3 genes are in genetic disequilibrium. This may imply that the three enzymes influence each other in complex, but as yet unknown, ways [52]. Alterations in the composition and/or structure of HDL particles in the course of development of CAD and MI have been little studied despite the known influence on PON1 activity, irrespective of the genotype [50].

5. Conclusions

This systematic review has sought to highlight the gaps in our knowledge of the role(s) that PON enzymes play in the pathogenesis of CAD. We propose the implementation of international, multicenter, multiethnic studies with larger sample sizes to analyze PON1, PON2 and PON3 genetic polymorphisms, the circulating enzyme concentrations and activities and relating these findings in the peripheral blood to changes occurring in tissue during the atherosclerosis process.
Acknowledgments

Data included in this review were generated from studies supported by grants from the Instituto de Salud Carlos III (PI1102817 and PI1100130), Madrid, Spain. Editorial assistance was provided by Peter R. Turner of Tscimed.com.

Author Contributions

David Abelló and Elena Sancho performed the bibliographic search that was further supervised by Jordi Camps and Jorge Joven. All authors contributed to writing the manuscript and read and approved the final version.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Primo-Parmo, S.L.; Sorenson, R.C.; Teiber, J.; La Du, B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33, 498–507.
2. Sorenson, R.C.; Primo-Parmo, S.L.; Camper, S.A.; La Du, B.N. The genetic mapping and gene structure of mouse paraoxonase/arylesterase. Genomics 1995, 30, 431–438.
3. Gupta, N.; Gill, K.; Singh, S. Paraoxonases: structure, gene polymorphism & role in coronary artery disease. Indian J. Med. Res. 2009, 130, 361–368.
4. Adkins, S.; Gan, K.N.; Mody, M.; La Du, B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 1993, 52, 598–608.
5. She, Z.-G.; Chen, H.-Z.; Yan, Y.; Li, H.; Liu, D.-P. The human paraoxonase gene cluster as a target in the treatment of atherosclerosis. Antioxid. Redox Signal. 2012, 16, 597–632.
6. Camps, J.; Marsillach, J.; Joven, J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit. Rev. Clin. Lab. Sci. 2009, 46, 83–106.
7. Hine, D.; Mackness, B.; Mackness, M. Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation. IUBMB Life. 2012, 64, 157–161.
8. Mackness, M.I.; Durrington, P.N.; Mackness, B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am. J. Cardiovasc. Drugs. 2004, 4, 211–217.
9. Mackness, M.I.; Mackness, B.; Durrington, P.N. Paraoxonase and coronary artery disease. Atheroscler. Suppl. 2002, 3, 49–55.
10. Costa, L.G.; Giordano, G.; Cole, T.B.; Marsillach, J.; Furlong, C.E. Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology 2013, 307, 115–122.
11. Khersonsky, O.; Tawfik, D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005, 44, 6371–6382.
12. Khersonsky, O.; Tawfik, D.S. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. Chembiochem. Eur. J. Chem. Biol. 2006, 7, 49–53.
13. Liu, T.; Zhang, X.; Zhang, J.; Liang, Z.; Cai, W.; Huang, M.; Yan, C.; Zhu, Z.; Han, Y. Association between PON1 rs662 polymorphism and coronary artery disease. *Eur. J. Clin. Nutr.* 2014, 68, 1029–1035.

14. Shekhanawar, M.; Shekhanawar, S.M.; Krisnaswamy, D.; Indumati, V.; Satishkumar, D.; Vijay, V.; Rajeshwari, T.; Amareshwar, M. The role of “paraoxonase-1 activity” as an antioxidant in coronary artery diseases. *J. Clin. Diagn. Res. JCDR* 2013, 7, 1284–1287.

15. Cozzi, L.; Campolo, J.; Parolini, M.; De Maria, R.; Patrosso, M.C.; Marocchi, A.; Parodi, O.; Penco, S. Paraoxonase 1 L55M, Q192R and paraoxonase 2 S311C alleles in atherothrombosis. *Mol. Cell. Biochem.* 2013, 374, 233–238.

16. Tang, W.H.W.; Hartiala, J.; Fan, Y.; Wu, Y.; Stewart, A.F.R.; Erdmann, J.; Kathiresan, S.; CARDIoGRAM Consortium; Roberts, R.; McPherson, R.; Allayee, H.; Hazen, S.L. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. *Arterioscler. Thromb. Vasc. Biol.* 2012, 32, 2803–2812.

17. Bayrak, A.; Bayrak, T.; Tokgözoglu, S.L.; Volkan-Salanci, B.; Deniz, A.; Yavuz, B.; Alikasifoglu, M.; Demirpençe, E. Serum PON-1 activity but not Q192R polymorphism is related to the extent of atherosclerosis. *J. Atheroscler. Thromb.* 2012, 19, 376–384.

18. Saxena T; Agarwal B.K.; Kare P. Serum paraoxonase activity and oxidative stress in acute myocardial infarction patients. *Biomed. Res.* 2011, 22, 215–219.

19. Gluba, A.; Pietrucha, T.; Banach, M.; Piotrowski, G.; Rysz, J. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. *Angiology* 2010, 61, 157–165.

20. Lakshmy, R.; Ahmad, D.; Abraham, R.A.; Sharma, M.; Vemparala, K.; Das, S.; Reddy, K.S.; Prabhakaran, D. Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infarction & association with oxidized low density lipoprotein. *Indian J. Med. Res.* 2010, 131, 522–529.

21. Regieli, J.J.; Jukema, J.W.; Doevendans, P.A.; Zwijersman, A.H.; Kastelein, J.J.; Grobbee, D.E.; van der Graaf, Y. Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. *J. Am. Coll. Cardiol.* 2009, 54, 1238–1245.

22. Jayakumari, N.; Thejaseebai, G. High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease. *J. Clin. Biochem. Nutr.* 2009, 45, 278–284.

23. Yildiz, A.; Gur, M.; Yilmaz, R.; Demirbag, R.; Polat, M.; Selek, S.; Celik, H.; Erel, O. Association of paraoxonase activity and coronary blood flow. *Atherosclerosis* 2008, 197, 257–263.

24. Saeed, M.; Perwaiz Iqbal, M.; Yousuf, F.A.; Perveen, S.; Shafiq, M.; Sajid, J.; Frossard, P.M. Interactions and associations of paraoxonase gene cluster polymorphisms with myocardial infarction in a Pakistani population. *Clin. Genet.* 2007, 71, 238–244.

25. Jarvik, G.P.; Hatsukami, T.S.; Carlson, C.; Richter, R.J.; Jampsa, R.; Brophy, VH.; Margolin, S.; Rieder, M.; Nickerson, D.; Schellenberg, G.D.; *et al.* Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. *Arterioscler. Thromb. Vasc. Biol.* 2003, 23, 1465–1471.
26. Domagała, T.B.; Łacinski, M.; Trzcianiak, W.H.; Mackness, B.; Mackness, M.I.; Jakubowski, H. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. *Cell. Mol. Biol.* **2006**, *52*, 4–10.

27. Su, S.; Chen, J.; Huang, J.; Wang, X.; Zhao, J.; Shen, Y.; Qiang, B.; Gu, D. Paraoxonase gene cluster variations associated with coronary heart disease in Chinese Han women. *Chin. Med. J. (Engl.)* **2005**, *118*, 1167–1174.

28. Rodríguez-Esparragón, F.; Rodríguez-Pérez, J.C.; Hernández-Trujillo, Y.; Macías-Reyes, A.; Medina, A.; Caballero, A.; Ferrario, C.M. Allelic variants of the human scavenger receptor class B type 1 and paraoxonase 1 on coronary heart disease: genotype-phenotype correlations. *Arterioscler. Thromb. Vasc. Biol.* **2005**, *25*, 854–860.

29. Kabaroglu, C.; Mutaf, I.; Boydak, B.; Ozmen, D.; Habif, S.; Erdener, D.; Parildo, Z.; Bayindir, O. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. *Acta. Cardiol.* **2004**, *59*, 606–611.

30. Srinivasan, S.R.; Li, S.; Chen, W.; Tang, R.; Bond, M.G.; Boerwinkle, E.; Berenson, G.S. Q192R polymorphism of the paraoxanase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community. The Bogalusa Heart Study. *Atherosclerosis* **2004**, *177*, 167–174.

31. Göçmen, A.Y.; Gümüşlü, S.; Semiz, E. Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease. *Clin. Cardiol. 2004*, 59, 426–430.

32. Oliveira, S.A.; Mansur, A.P.; Ribeiro, C.C.; Ramires, J.A.F.; Annichino-Bizzacchi, J.M. PON1 M/L55 mutation protects high-risk patients against coronary artery disease. *Int. J. Cardiol.* **2004**, *94*, 73–77.

33. Robertson, K.S.; Hawe, E.; Miller, G.J.; Talmud, P.J.; Humphries, S.E. Northwick Park Heart Study II Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. *Biochim. Biophys. Acta* **2003**, *1639*, 203–212.

34. Wang, X.; Fan, Z.; Huang, J.; Su, S.; Yu, Q.; Zhao, J.; Hui, R.; Yao, Z.; Shen, Y.; Qiang, B.; Gu, D. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. *Arterioscler. Thromb. Vasc. Biol.* **2003**, *23*, 328–334.

35. Fortunato, G.; Rubba, P.; Panico, S.; Trono, D.; Tinto, N.; Mazzaccara, C.; de Michele, M.; Iannuzzi, A.; Vitale, D.F.; Salvatore, F.; et al. A paraoxonase gene polymorphism, PON 1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women. *Atherosclerosis* **2003**, *167*, 141–148.

36. Rahmani, M.; Raiszadeh, F.; Allahverdian, S.; Kiai, S.; Navab, M.; Azizi, F. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. *Atherosclerosis* **2002**, *162*, 381–389.

37. Ferré, N.; Tous, M.; Paul, A.; Zamora, A.; Vendrell, J.J.; Bardají, A.; Camps, J.; Richart, C.; Joven, J. Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. *Clin. Biochem.* **2002**, *35*, 197–203.

38. Hong, S.H.; Song, J.; Min, W.K.; Kim, J.Q. Genetic variations of the paraoxonase gene in patients with coronary artery disease. *Clin. Biochem.* **2001**, *34*, 475–481.
39. Malin, R.; Järvinen, O.; Sisto, T.; Koivula, T.; Lehtimäki, T. Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis. *Atherosclerosis* **2001**, *157*, 301–307.

40. Gardemann, A.; Philipp, M.; Hess, K.; Katz, N.; Tillmanns, H.; Haberbosch, W. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. *Atherosclerosis* **2000**, *152*, 421–431.

41. Cascorbi, I.; Laule, M.; Mrozikiewicz, P.M.; Mrozikiewicz, A.; Andel, C.; Baumann, G.; Roots, I.; Stangl, K. Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. *Pharmacogenetics* **1999**, *9*, 755–761.

42. Sanghera, D.K.; Aston, C.E.; Saha, N.; Kamboh, M.I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. *Am. J. Hum. Genet.* **1998**, *62*, 36–44.

43. Ombres, D.; Pannitteri, G.; Montali, A.; Candeloro, A.; Seccareccia, F.; Campagna, F.; Cantini, R.; Campa, P.P.; Ricci, G.; Arca, M. The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. *Arterioscler. Thromb. Vasc. Biol.* **1998**, *18*, 1611–1616.

44. Suehiro, T.; Nakauchi, Y.; Yamamoto, M.; Arii, K.; Itoh, H.; Hamashige, N.; Hashimoto, K. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. *Int. J. Cardiol.* **1996**, *57*, 69–73.

45. Herrmann, S.M.; Blanc, H.; Poirier, O.; Arveiler, D.; Luc, G.; Evans, A.; Marques-Vidal, P.; Bard, J.M.; Cambien, F. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. *Atherosclerosis* **1996**, *126*, 299–303.

46. McElveen, J.; Mackness, M.I.; Colley, C.M.; Peard, T.; Warner, S.; Walker, C.H. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. *Clin. Chem.* **1986**, *32*, 671–673.

47. Gaidukov, L.; Tawfik, D.S. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. *J. Lipid Res.* **2007**, *48*, 1637–1646.

48. Parra, S.; Marsillach, J.; Aragonès, G.; Rull, A.; Beltrán-Debón, R.; Alonso-Villaverde, C.; Joven, J.; Camps, J. Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients. *Lipids Health Dis.* **2010**, *9*, doi:10.1186/1476-511X-9-32.

49. Aviram, M.; Vaya, J. Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion. *Curr. Opin. Lipidol.* **2013**, *24*, 339–344.

50. Furlong, C.E.; Richter, R.J.; Li, W.F.; Brophy, V.H.; Carlson, C.; Rieder, M.; Nickerson, D.; Costa, L.G.; Ranchalis, J.; Lusis, A.J.; et al. The functional consequences of polymorphisms in the human PON1 gene. In *The paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism*; Springer: Dordrecht, The Netherlands, 2008; Volume 6, pp. 267–281.

51. Marsillach, J.; Aragonès, G.; Beltrán, R.; Caballeria, J.; Pedro-Botet, J.; Morcillo-Suárez, C.; Navarro, A.; Joven, J.; Camps, J. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. *Clin. Biochem.* **2009**, *42*, 91–98.
53. Camps, J.; Mackness, M.; Mackness, B.; Marsillach, J.; Joven, J. Serum paraoxonase-1 activity and genetic polymorphisms: common errors in measurement and interpretation of results. *Clin. Chem. Lab. Med.* **2010**, *48*, 893–894.

54. Marsillach, J.; Camps, J.; Beltran-Debón, R.; Rull, A.; Aragones, G.; Maestre-Martínez, C.; Sabench, F.; Hernández, M.; Castillo, D.D.; Joven, J.; *et al*. Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. *Eur. J. Clin. Invest.* **2011**, *41*, 308–314.

55. Fortunato, G.; Di Taranto, M.D.; Bracale, U.M.; Del Guercio, L.; Carbone, F.; Mazzaccara, C.; Morgante, A.; D’Armiento, F.P.; D’Armiento, M.; Porcellini, M.; *et al*. Decreased paraoxonase-2 expression in human carotids during the progression of atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* **2008**, *28*, 594–600.

56. Tavori, H.; Vaya, J.; Aviram, M. Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activity. *Adv. Exp. Med. Biol.* **2010**, *660*, 99–111.

57. Martinelli, N.; Consoli, L.; Girelli, D.; Grison, E.; Corrocher, R.; Olivieri, O. Paraoxonases: ancient substrate hunters and their evolving role in ischemic heart disease. *Adv. Clin. Chem.* **2013**, *59*, 65–100.

58. Liu, H.; Xia, P.; Liu, M.; Ji, X.M.; Sun, H.B.; Tao, L.; Mu, Q.W. PON gene polymorphisms and ischaemic stroke: a systematic review and meta analysis. *Int. J. Stroke* **2013**, *8*, 111–123.

59. Précourt, L.-P.; Amre, D.; Denis, M.-C.; Lavoie, J.-C.; Delvin, E.; Seidman, E.; Levy, E. The three-gene paraoxonase family: physiologic roles, actions and regulation. *Atherosclerosis* **2011**, *214*, 20–36.

60. Ng, C.J.; Shih, D.M.; Hama, S.Y.; Villa, N.; Navab, M.; Reddy, S.T. The paraoxonase gene family and atherosclerosis. *Free Radic. Biol. Med.* **2005**, *38*, 153–163.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).